Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

What Was Tested

The trial (phase 1) is built around Semaglutide and Liraglutide.

The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected).

The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.

It had three arms (groups): Liraglutide (experimental), Oral semaglutide (experimental) and Semaglutide (experimental).

Participants will receive liraglutide subcutaneously.

Participants will receive semaglutide orally.

Participants will receive semaglutide subcutaneously.

The registry classes the interventions as drug.

Who Took Part

The registry lists 71 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female. Age 18 years or above at the time of signing the informed consent. BMI between 25.0 and 45 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. Diagnosed with type 2 diabetes (T2D) more than (\>) 180 days before screening. No antidiabetic drugs or.

The full record lists 7 inclusion and 9 exclusion criteria; among the exclusions: use of other medications known to affect the motility of the stomach; inability to lie in the right lateral decubitus position for gastric ultrasonography; unusual meal habits and special diet requirements or unwillingness to eat the meals provided in the study.

How the Study Was Run

It was run as a non-randomized, parallel-group and open-label study.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2025-11-07 with completion listed for 2026-12-13.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 36 secondary outcomes, for example Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal (Yes/No), Gastric volume after fasting following a solid, high-fat meal, Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal (Yes/No), Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal (Yes/No), Gastric volume after fasting following a liquid meal and Presence of solids in the stomach (antrum grade 'solid') after fasting following a liquid meal (Yes/No).

What This Means in Plain Language

Put simply, this is a phase 1, non-randomized trial of Semaglutide and Liraglutide in 71 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page and the Liraglutide compound page, all human trials.